{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:38:39Z","timestamp":1794328719000,"version":"4.9.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eururo.2026.03.021","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:52:56Z","timestamp":1777319576000},"page":"163-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["European Association of Urology Guidelines on Testicular Cancer: Summary of the 2026 Guidelines"],"prefix":"10.1016","volume":"90","author":[{"given":"Anna","family":"Patrikidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Oing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Berney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fankhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Leao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gravina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Di","family":"Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cornes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Janisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Bezuidenhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hege Sagstuen","family":"Haugnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Papachristofilou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torgrim","family":"Tandstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.03.021_b0005","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012390","article-title":"Recent global trends in testicular cancer incidence and mortality","volume":"97","author":"Park","year":"2018","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.eururo.2026.03.021_b0010","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00345-014-1361-y","article-title":"Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009","volume":"33","author":"Nigam","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0015","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2019.07.002","article-title":"International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries","volume":"76","author":"Gurney","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2015.07.044","article-title":"Guidelines on testicular cancer: 2015 update","volume":"68","author":"Albers","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology guidelines on testicular cancer: 2023 update","volume":"84","author":"Patrikidou","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0030","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.juro.2009.07.045","article-title":"Clinicopathological study of regressed testicular tumors (apparent extragonadal germ cell neoplasms)","volume":"182","author":"Angulo","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0035","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0302-2838(02)00439-6","article-title":"Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumors of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG)","volume":"42","author":"Germ\u00e0-Lluch","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00345-021-03876-2","article-title":"Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumors clinical stage 1","volume":"40","author":"Dieckmann","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0045","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.eururo.2021.06.006","article-title":"Circulating microRNAs, the next-generation serum biomarkers in testicular germ cell tumors: a systematic review","volume":"80","author":"Le\u00e3o","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0050","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00432-020-03429-x","article-title":"Serum levels of microRNA-371a-3p are not elevated in testicular tumors of non-germ cell origin","volume":"147","author":"Belge","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2020.02.023","article-title":"Testis-sparing surgery and scrotal violation for testicular masses suspicious for malignancy: a systematic review and meta-analysis","volume":"38","author":"Patel","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0060","doi-asserted-by":"crossref","first-page":"605e.19","DOI":"10.1016\/j.urolonc.2020.03.012","article-title":"Partial orchiectomy: the Princess Margaret cancer center experience","volume":"38","author":"Nason","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0065","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.juro.2018.03.007","article-title":"Testis sparing surgery for benign testicular masses: diagnostics and therapeutic approaches","volume":"200","author":"Paffenholz","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0070","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.eururo.2006.05.051","article-title":"Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy","volume":"51","author":"Dieckmann","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0075","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/annonc\/mdi175","article-title":"Carcinoma in situ testis, the progenitor of testicular germ cell tumors: a clinical review","volume":"16","author":"Hoei-Hansen","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0080","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1200\/JCO.2002.20.6.1537","article-title":"Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis","volume":"20","author":"Petersen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0085","unstructured":"Brierley JD, Giuliani M, O\u2019Sullivan B, Rous B, Van Eycken E. The TNM Classification of Malignant Tumours ed. 9 2025;2025, https:\/\/www.uicc.org\/news-and-updates\/25-7-announcements\/9th-edition-uicc-tnm-classification-malignant-tumours-now-available."},{"key":"10.1016\/j.eururo.2026.03.021_b0090","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","article-title":"International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group","volume":"15","author":"Mead","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0095","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.20.03296","article-title":"Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium","volume":"39","author":"Gillessen","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0100","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.20.03292","article-title":"Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium","volume":"39","author":"Beyer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0105","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.euo.2025.01.006","article-title":"Redefining good-prognosis seminoma: implications for clinical practice of the updated International Germ Cell Cancer Collaborative Group classification and results from the SEMITrends survey","volume":"8","author":"Patrikidou","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.euo.2023.10.014","article-title":"Prognostic factor risk groups for clinical Stage I seminoma: an individual patient data analysis by the European Association of Urology testicular cancer guidelines panel and guidelines office","volume":"7","author":"Boormans","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JCO.23.00959","article-title":"Prognostic factors for relapse in patients with clinical stage I testicular seminoma: A nationwide, population-based cohort study","volume":"42","author":"Wagner","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114025","article-title":"Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study","volume":"202","author":"Wagner","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2026.03.021_b0125","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.euf.2020.06.012","article-title":"Cost-effectiveness analysis of non-risk-adapted active surveillance for postorchiectomy management of clinical Stage I seminoma","volume":"7","author":"Huang","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.03.021_b0130","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1200\/JCO.21.01199","article-title":"Imaging modality and frequency in surveillance of Stage I seminoma testicular cancer: results from a randomized, Phase III, noninferiority trial (TRISST)","volume":"40","author":"Joffe","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0135","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.critrevonc.2007.04.014","article-title":"A comprehensive systematic review of testicular germ cell tumor surveillance","volume":"64","author":"Groll","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2026.03.021_b0140","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s00345-022-04145-6","article-title":"Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review","volume":"40","author":"Ruf","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0145","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/annonc\/mdw164","article-title":"Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)","volume":"27","author":"Tandstad","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0150","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(05)66984-X","article-title":"Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial","volume":"366","author":"Oliver","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.03.021_b0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","article-title":"Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance","volume":"33","author":"Kollmannsberger","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0160","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.eururo.2010.08.032","article-title":"Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumors: long-term outcome and analysis of risk factors of recurrence","volume":"58","author":"Nicolai","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0165","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.juro.2017.09.088","article-title":"Laparoscopic retroperitoneal lymph node dissection for clinical Stage I nonseminomatous germ cell tumors of the testis: safety and efficacy analyses at a high volume center","volume":"199","author":"Nicolai","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0170","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.urology.2013.04.082","article-title":"Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy","volume":"82","author":"Al-Ahmadie","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.03.021_b0175","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1200\/JCO.2008.18.8953","article-title":"Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program","volume":"27","author":"Tandstad","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0180","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1200\/JCO.19.01876","article-title":"Outcome of men with relapses after adjuvant bleomycin, etoposide, and cisplatin for clinical Stage I nonseminoma","volume":"38","author":"Fischer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0185","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO.2003.06.065","article-title":"Radiotherapy for stages IIA\/B testicular seminoma: final report of a prospective multicenter clinical trial","volume":"21","author":"Classen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0190","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdu447","article-title":"Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes","volume":"26","author":"Giannatempo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0195","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.22.00624","article-title":"Surgery in early metastatic seminoma: A Phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2022.10.021","article-title":"Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA\/B (PRIMETEST)","volume":"84","author":"Hiester","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0205","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.euo.2023.06.004","article-title":"Retroperitoneal lymph node dissection in clinical stage IIA\/B metastatic seminoma: results of the COlogne trial of retroperitoneal lymphadenectomy in metastatic seminoma (COTRIMS)","volume":"7","author":"Heidenreich","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0210","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.eururo.2022.04.031","article-title":"The GETUG SEMITEP trial: de-escalating chemotherapy in good-prognosis seminoma based on fluorodeoxyglucose positron emission tomography\/computed tomography","volume":"82","author":"Loriot","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0215","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S1470-2045(22)00564-2","article-title":"Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01\/10): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Papachristofilou","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euros.2024.05.006","article-title":"Primary retroperitoneal lymph node dissection as treatment for low-volume metastatic seminoma in a population-based cohort: the Swedish Norwegian Testicular Cancer Group experience","volume":"65","author":"Thor","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2026.03.021_b0225","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JU.0000000000003697","article-title":"Primary retroperitoneal lymph node dissection for seminoma metastatic to the retroperitoneum","volume":"211","author":"Matulewicz","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0230","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.euf.2022.11.003","article-title":"Treatment outcomes for men with clinical Stage II nonseminomatous germ cell tumors treated with primary retroperitoneal lymph node dissection: A systematic review","volume":"9","author":"Neuenschwander","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.03.021_b0235","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/bjc.1998.587","article-title":"Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer","volume":"78","author":"de Wit","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2026.03.021_b0240","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.1998.16.4.1287","article-title":"Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study","volume":"16","author":"Nichols","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0245","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1200\/JCO.2004.04.008","article-title":"Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors","volume":"22","author":"Fizazi","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0250","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/S1470-2045(14)70490-5","article-title":"Personalised chemotherapy based on tumor marker decline in poor prognosis germ-cell tumors (GETUG 13): a phase 3, multicentre, randomized trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0255","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.23.01960","article-title":"Personalized chemotherapy on the basis of tumor marker decline in poor-prognosis germ-cell tumors: updated analysis of the GETUG-13 Phase III trial","volume":"42","author":"Fizazi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0260","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/annonc\/mdr052","article-title":"2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial","volume":"23","author":"Bachner","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0265","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00210","article-title":"Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an international global germ cell cancer group registry","author":"Cathomas","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0270","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1756287212443170","article-title":"Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice","volume":"4","author":"Heidenreich","year":"2012","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.eururo.2026.03.021_b0275","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.931509","article-title":"A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumors","volume":"12","author":"Conduit","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2026.03.021_b0280","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2008.09.027","article-title":"Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection","volume":"55","author":"Heidenreich","year":"2009","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826020579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826020579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:27:04Z","timestamp":1785886024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826020579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0302283826020579"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.03.021","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Association of Urology Guidelines on Testicular Cancer: Summary of the 2026 Guidelines","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.04.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}